NCT02278068View on ClinicalTrials.gov

COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
DiabetesEndocrine, Nutritional and Metabolic Diseases (E00-E89)
Interventions
DEVICE

Metabolic Neuromodulation System (MNS)

Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.

Trial Locations (6)

Unknown

Auckland City Hospital, Auckland

Middlemore Hospital, Auckland

North Shore Hospital, Auckland

Christchurch Hospital, Christchurch

Dunedin Hospital, Dunedin

Wellington Hospital, Wellington

Sponsors

Lead Sponsor

Metavention
All Listed Sponsors
lead

Metavention

INDUSTRY

NCT02278068 - COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy | Biotech Hunter | Biotech Hunter